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Polymorphism in pathogen antigens presents a complex challenge for vaccine design. A prime example is the
N-terminal block 2 region of the Plasmodium falciparum merozoite surface protein 1 (MSP1), to which
allele-specific antibodies have been associated with protection from malaria. In a Zambian population studied
here, 49 of 91 alleles sampled were of the K1-like type (the most common of three block 2 types in all African
populations), and most of these had unique sequences due to variation in tri- and hexapeptide repetitive motifs.
There were significant negative correlations between allelic sequence lengths of different regions of the repeats,
so the complete repeat sequence had less length variation than its component parts, suggesting a constraint on
overall length. Diverse epitopes recognized by three murine monoclonal antibodies and 24 individual human
sera were then mapped by using a comprehensive panel of synthetic peptides, revealing epitopes in all regions
of the repeats. To incorporate these different epitopes in a single molecule, a composite sequence of minimal
overall length (78 amino acids) was then designed and expressed as a recombinant antigen. More human
immune sera reacted with this “K1-like Super Repeat” antigen than with proteins consisting of single natural
allelic sequences, and immunization of mice elicited antibodies that recognized a range of five cultured parasite
lines with diverse K1-like MSP1 block 2 repeat sequences. Thus, complex allelic polymorphism was decon-
structed and a minimal composite polyvalent antigen was engineered, delivering a designed candidate sequence
for inclusion in a malaria vaccine.
Multiple serotype vaccines have been designed against bac-
terial infections, based on the commonly prevalent serotypes of
polysaccharide (20) or protein antigens (16, 25). The potential
effectiveness of complex multivalent formulations has been
well illustrated by protein-conjugate vaccines against Strepto-
coccus pneumoniae, with evidence of strong serotype-specific
immunity in vaccine trials and a decline in overall incidence of
disease in vaccinated populations (9), although concerns about
serotype replacement remain (23). Evolutionary analyses have
been advocated as a means to design vaccines against geneti-
cally dynamic pathogen populations, either targeted to a pre-
dicted future epidemic strain (2) or to give the most relevant
immunization against globally diverse strains (13).
The malaria parasite Plasmodium falciparum exhibits exten-
sive antigenic diversity, due to its complex life cycle and, par-
ticularly, allelic forms of genetically polymorphic proteins or
clonally variant expression of multigene families. Although
there is no universal strategy for the design of a vaccine against
P. falciparum malaria, it is widely recognized that some of the
existing diversity should be incorporated (33). Experimental
vaccines incorporating antigens from different life cycle stages
(35) or different antigens from the asexual blood stage (14)
have been tested in humans and, although not all have given
significant protection, they confirm that immune responses can
be elicited by combinations of different antigens. An experi-
ment in nonhuman primates suggests that responses to each
component antigen may not be compromised by such a com-
bination (17).
A case can be made for focusing on polymorphic variants of
one or two important antigens. Molecular population genetic
analyses of antigen genes reveals patterns of diversifying selec-
tion in particular sequence regions and thus points to potential
targets of protective immunity. Antigens of P. falciparum that
appear to be under such selection include the merozoite apical
membrane antigen 1 (AMA1) (30, 31) and the merozoite sur-
face proteins 1 (MSP1) (7) and MSP2 (6). For each of these
antigens, there is also evidence from epidemiological studies or
in vitro parasite inhibition assays that allele-specific antibodies
have a protective effect (1, 7, 15, 19, 21, 24, 26, 27, 34).
A region near the N terminus of P. falciparum MSP1, des-
ignated “block 2” (28), is the most polymorphic part of the
antigen and appears to be under the strongest diversifying
selection within natural populations (7). There are three major
allelic types of block 2, two of which are targets of naturally
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acquired antibodies that are associated with significant protec-
tion from clinical malaria (3, 7). One of these, the K1-like type,
is the most common in all African populations (7) and contains
the most complex subtype sequence diversity due to variation
in different tri- and hexapeptide repeat sequences (28). Al-
though subtype-specific human antibodies to K1-like repeats
have been described (4, 5) and are associated with protection
from clinical malaria (32), the adaptive significance of the
extensive repeat sequence polymorphism is not clearly under-
stood. The present study explores the statistical distribution of
sequence length variation in different parts of the K1-like re-
peats and identifies the primary sequences that are recognized
by murine monoclonal and human serum antibodies. The in-
formation is then used to design and construct a minimal
composite repeat sequence antigen that encompasses diverse
subtype-restricted epitopes and elicits a broader antibody rep-
ertoire compared to individual allelic proteins after immuni-
zation.
MATERIALS AND METHODS
Sequencing of P. falciparum msp1 block 2 from Zambian samples. A portion of
the msp1 gene spanning the block 2 region was amplified from genomic DNA
isolated from peripheral blood samples of 91 individuals with P. falciparum
infections in northern Zambia. PCR primers BK1F and BK3R that annealed to
conserved sequences in block 1 and block 3 were used with amplification con-
ditions described previously (8). Amplification products were run and visualized
on 2% agarose gels. Allelic sizes of the gene fragment range from ca. 400 to 600
bp, and many isolates contain more than one genetic type of P. falciparum, so the
predominant band was excised for each isolate. This was then purified and DNA
sequencing of both strands was performed directly using the BK1F and BK3R
primers using BigDye v3.1 chemistry and electrophoresis on an ABI 377 se-
quencer (Applied Biosystems). Sequence data for each isolate were visually
examined for the quality of every nucleotide using the Sequence Navigator
program, with PCR and sequencing reactions being repeated in the case of any
uncertainty. The data from the whole population sample were then compiled by
using the MEGALIGN program (DNAStar, Inc., Madison, WI). The deduced
amino acid sequences of the MSP1 block 2 repeats were examined, with separate
regions of the repeats being analyzed for mean and variance in sequence length,
using the statistical software SPSS version 11.0.
Human sera and murine MAbs. Sera from 78 West African adults, 38 subjects
(aged 18 to 60 years) from Lagos in Nigeria (29), and 40 adults (aged 22 to 70
years) from the village of Brefet in The Gambia were studied here by enzyme-
linked immunosorbent assay (ELISA) and (for a subset of the sera) in synthetic
peptide immunoassays. Twenty sera from adults living in the United Kingdom,
who had never had malaria were used as negative controls. All of these samples
were obtained with informed consent, under the approval of the relevant local
and institutional ethical committees. Four murine monoclonal antibodies
(MAbs) were studied. Specificities for some allelic products of the K1-like type
of MSP1 block 2 were known for MAbs 12.2, 123D3, and CE2 (5, 24); MAb 12.1,
known to react with MSP1 block 4, was used as a control.
Synthetic peptides. Twenty-three peptides, each 12 amino acids in length, were
synthesized onto a cellulose solid support (Whatman) by using methods de-
scribed (12). These peptides were designed to represent all of the deduced
12-mer amino acid sequences contained in the repeat region of all P. falciparum
K1-like MSP1 block 2 alleles found in the GenBank database and in the present
study, starting with a serine at position one (rather than positions two or three)
of each tripeptide repeat. As controls for type-specific reactivity, 24 synthetic
peptides of the MAD20-like allelic type (representing all of the known 12-mer
repeat sequences starting with a serine) and 12 synthetic peptides of the RO33-
like type (all contiguous peptides overlapping by nine amino acids spanning this
nonrepeat allelic sequence) were also synthesized and tested with antibodies.
Peptide immunoassay. Replicate peptide arrays on cellulose membranes were
incubated in blocking solution (Tris-buffered saline [TBS]–Tween 20 [T-20], 5%
sucrose, 2% bovine serum albumin, and 3% skimmed milk powder) at 4°C
overnight. Each membrane was drained on filter paper to remove excess blocking
solution and then incubated with a 1/500 dilution of serum (or MAbs diluted as
specified) in fresh blocking solution and stored at 4°C. The following day, the
membranes were washed twice in each of the following Tris-based solutions:
TBS–T-20, TBS–T-20–NaCl, TBS–T-20–Triton X-100, and TBS–T-20. The
membranes were blotted dry and then incubated with a 1/5,000 dilution of
horseradish peroxidase-conjugated goat anti-human immunoglobulin G (IgG;
Dako) in blocking solution for 4 h. The membranes were washed twice in each
of the above solutions followed by two washes in TBS. The membranes were
blotted dry of excess buffer, and results visualized after development in stabilized
TMB substrate (Promega) for 2 min. Reactivity was scored independently by two
investigators, and a consensus then obtained (each spot was scored as strong,
weak, or negative), with assays being repeated in the case of any uncertainty.
Construction and expression of the K1 Super Repeat recombinant protein. A
synthetic gene sequence encoding the “Super Repeat” construct was codon
optimized and synthesized with terminal BamHI and EcoRI sites for cloning
(GeneArt, Regensburg, Germany). The sequence was subcloned from the
pPCR-Script vector into pGEX-2T to be expressed as a glutathione S-transferase
(GST) fusion protein in Escherichia coli BL21(DE3) cells. Expression and puri-
fication followed manufacturers’ protocols, as described previously for other
MSP1 block 2 recombinant proteins (5, 32).
Mouse immunizations. Five MF1 outbred mice were immunized with the K1
Super Repeat recombinant protein according to a protocol used elsewhere for
the immunization of other MSP1 block 2 recombinant proteins (5, 32). All
animals were given three 50-g doses of purified protein in the adjuvant Imject-
Alum (Pierce) at monthly intervals; serum was collected before immunization
and 12 to 14 days after each dose.
ELISAs. A total of 50 ng/well of each recombinant antigen was coated over-
night at 4°C in 100 l of coating buffer (15 mM Na2CO3, 35 mM NaHCO3 [pH
9.3]) onto Immulon 4HBX flat-bottom microtiter plates (Dynex Technologies,
Inc.). Plates were washed (in phosphate-buffered saline with 0.05% T-20),
blocked (1% skimmed milk in PBS with Tween) for 5 h, and washed again. MAbs
were diluted as indicated, sera were diluted 1/500, and duplicate 100-l aliquots
in blocking buffer were incubated overnight at 4°C in antigen-coated wells. The
wells were washed and then incubated with 100 l of horseradish peroxidase-
conjugated goat anti-human IgG (at 1/5,000) before detection with o-phenylene-
diamine–H2O2 (Sigma). The mean optical density (OD) value of each serum-
antigen reaction was calculated after correction for binding of the serum to GST
alone (this background OD was generally 0.1). A serum was scored as positive
if the corrected OD value was higher than the mean plus three standard devia-
tions of values of 20 negative control sera from United Kingdom residents who
had never had malaria.
IFA. The immunofluorescence assay (IFA) was performed as described for
sera raised to other MSP1 block 2 antigens (5, 32). Acetone-fixed multiwell slides
of schizonts from five P. falciparum cultured lines (Palo Alto, 3D7, T9/96, T9/102,
and K1) were probed with the murine sera raised against the K1 Super Repeat
(at doubling dilutions from 1/50 up to 1/51,200). Endpoint titers were stringently
determined and are expressed as the highest dilution that still gave clear schi-
zont-specific fluorescence (“” on a “” to “” visual scoring scheme).
RESULTS
Ninety-one Zambian alleles of msp1 block 2 were se-
quenced, of which 49 (54%) were of the K1-like type, 32 (35%)
were of the RO33-like type, and 10 (11%) were of the MAD20-
like type. Figure 1A shows the repeat sequences of the K1-like
alleles, revealing 39 different allelic sequences out of 49 sam-
pled. All alleles had the core sequence motif SAQSGT, with
various repeated permutations of this hexapeptide or the SGT
tripeptide component. C terminal to this, all except two of the
alleles had the SGPSGT sequence motif, with repeated per-
mutations of this hexapeptide or the SGP or SGT tri-peptide
components. At the N terminus of the repeats, some alleles
had the SAQSGA motif, with repeated permutations of this.
An analysis of variation in sequence length was done on the
repeats overall and on each of the component regions, which
were strictly defined as outlined in the legend to Fig. 1. Al-
though the variance in the overall repeat length was consider-
able (mean amino acid length of repeats  35.6, variance 
146.1), it was much less than the sum of the variance in the
length of each of the repeat subregions (SAQSGT region,
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mean 23.1, variance 196.6; SGPSGT region, mean 10.0,
variance  43.6; SAQSGA region, mean  2.6, variance 
36.0). This was due to significantly nonrandom negative corre-
lations between the lengths of the different repeat subregions
in each allele (SAQSGT region versus SAQSGA region, r 
0.50, P  0.001 [Fig. 1B]; SAQSGT region versus SGPSGT
region, r  0.33, P  0.022 [Fig. 1C]). These findings suggest
a selective constraint on overall sequence length, so that mu-
FIG. 1. (A) Schematic representation of sequences of the repeats of the K1-like type of MSP1 block 2 in 49 alleles of this type sampled in
northern Zambia. (B) Negative correlation between the amino acid length of sequence in the N-terminal part of the repeats (SAQSGA region
[defined as starting at the first SAQ and ending at the last SGA]) and the central part of the repeats (SAQSGT region [defined as starting at the
first SAQSGT and ending at the last SGT before an SGP]). (C) Negative correlation between the amino acid length of sequence in the C-terminal
part of the repeats (SGTSGP region [defined as starting at the first SGP and ending at the last SGT]) and the central part of the repeats (SAQSGT
region [defined as described above]).
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FIG. 2. Reactivities of different antibodies against a panel of 23 synthetic peptides representing 12-mer amino acid repeat sequences in the
K1-like type of MSP1 block 2. Peptides are arrayed in three vertical columns of 8, 8, and 7 spots on the membranes, and the identities of these
peptide sequences are listed to the right of each membrane (reading downward for each column of spots and beginning with the left-hand column).
The sequences corresponding to the spots that are visibly reactive with a given antibody are highlighted in boldface, and the minimal deduced
epitope sequences are shown underneath. (A) Reactivity of two murine MAbs known to react with the K1-like type of MSP1 block 2. (B) Reactivity
of two human sera from adults living in areas of endemicity in Africa.
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tational expansion of one region of the repeats leads to a lower
fitness unless it is counterbalanced by contraction of another
region.
To identify epitopes in these repeat sequences, antibodies
were assayed against a panel of 23 synthetic peptides, repre-
senting all of the 12-mer amino acid sequences (with the serine
of tripeptides at position 1) in K1-like repeats of block 2
sequences derived globally. Three murine MAbs—12.2,
123D3, and CE2—known to react with MSP1 block 2 of the
K1-like type were tested. Each of these MAbs had a different
profile of reactivity with the K1-like synthetic peptides (Fig. 2A
illustrates the positive reactivity of MAb 12.2 against six of the
peptides and of MAb 123D3 against two of the peptides).
None reacted with any of the MAD20-like or RO33-like pep-
tide controls, and a negative control antibody MAb 12.1
(against block 4 of MSP1) was not reactive with any of the
FIG. 3. (A) Scheme showing the reactivities of murine MAbs (12.2, 123D3, and CE2 against MSP1 block 2) and a negative control (12.1 against
block 4), and 24 sera from adult Africans (12 from Lagos, Nigeria, and 12 from Brefet village in The Gambia) and a representative European
control serum (E1). (B) Deduced specificity of three murine MAbs and antibodies in each of 24 human sera, 12 from Nigeria (N) and 12 from
The Gambia (G), given as horizontal lines mapping to different parts of a schematic composite K1-like Super Repeat sequence of MSP1 block 2.
In cases where a deduced specificity maps to more than one place in the Super Repeat sequence, it is visually shown only once (at the most
N-terminal occurrence).
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peptides. From examining the reactivity profiles, the minimal
primary sequence specificities were deduced as SGASAQSG
for MAb 12.2, SAQSGTSGTS for MAb 123D3, and SAQSG
TSGT for MAb CE2. The peptides were designed to have
serine at the first position of each tripeptide repeat rather than
the second or third, so it is not known whether the terminal
one or two amino acids are essential in the case of some
deduced specificities.
Twelve sera from Nigerian adults and twelve from Gambian
adults that had antibodies to MSP1 block 2 recombinant pro-
teins as assayed by ELISA were then tested to see whether the
specificities of human antibodies could be deduced with the
synthetic peptide array. Each serum reacted with between
three and nine different peptides. Reactivities of two of the
sera are shown in Fig. 2B, and scored results of all are given in
Fig. 3A. From each of these reactivity profiles, between one
and three distinct specificities were deduced to be present in
each serum (for a few sera there was also evidence of addi-
tional weaker reactivities). A composite repeat sequence was
designed that encompassed the different deduced specificities
within the minimal overall sequence length (Fig. 3B).
To express this composite of repeats (Fig. 3B) as an antigen,
a novel DNA sequence was constructed and cloned into the
pGEX plasmid for expression as a GST fusion protein in E.
coli. This K1-like Super Repeat antigen was expressed abun-
dantly in soluble form and purified on a glutathione column
(Fig. 4A). This new recombinant antigen reacted specifically
with each of the three MAbs against epitopes in the K1-like
repeat sequences (Fig. 4B) and with Nigerian and Gambian
adult sera (Fig. 4C) (see Fig. S1A and B in the supplemental
material). Significantly, the Super Repeat antigen shows a
broader reactivity with these antibodies than the antigens ex-
pressing individual alleles (Fig. 4B and C).
Mice immunized with the K1-like Super Repeat antigen
produced antibodies to different primary sequence determi-
nants as determined by peptide immunoassay (Fig. 5A). Inter-
estingly, all five mice produced antibodies against the SGTSG
TSGT epitope, although the remaining antibody profile
differed between each animal. As a comparison, sera from
mice previously immunized with distinct K1-like repeat anti-
gens (3D7 and Palo Alto) were also tested against the panel of
K1-like synthetic peptides, demonstrating a narrower range of
specific reactivities (Fig. 5A). Mice immunized with the 3D7
repeat sequence antigen showed a profile of reactivity encom-
passing the SAQSGASAQ and SGASAQS motifs (in the N-
terminal part of the repeat array). The mice immunized with
the Palo Alto repeat sequence antigen reacted with the central
motifs containing permutations of the SAQ and SGT se-
quences (Fig. 5A). In contrast, mice immunized with the K1
Super Repeat recognized more diverse repeat sequence
epitopes located in the N-terminal, central, and C-terminal
subregions.
Antibody reactivity was then tested against a panel of five P.
falciparum cultured lines with different repeat sequences of the
K1-like MSP1 block 2 (Fig. 5B) by immunofluorescence with
parasite schizonts. All mice produced antibodies with endpoint
titers of at least 1/6,400 against schizonts of at least one of the
cultured lines. The profile of reactivity to different parasites
varied among the mice (Fig. 5B) in a manner consistent with
the deduced specificity of the antibodies to particular repeat
sequences (Fig. 5A). For example, most mice recognized all of
the parasite lines, although mice 3 and 4 did not recognize
T9/96 and 3D7 (Fig. 5B), parasite lines that did not have the
primary sequence motifs that were defined for the antibodies
of these mice (Fig. 5A).
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FIG. 4. (A) Coomassie-stained sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels showing expressed MSP1 block 2 K1-like Super
Repeat GST fusion protein (lane 1) and the GST carrier alone (lane 2). (B) MAb reactivities to the MSP1 block 2 K1-like Super Repeat protein
by ELISA. (C) Scatterplot of ELISA OD values for IgG reactivity to the K1-like Super Repeat and to each of two single allele repeat antigens
(Palo Alto and 3D7) in 78 adult West African sera (38 from Nigeria and 40 from The Gambia).
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DISCUSSION
Detecting evidence of selection on repeat sequences is not
straightforward. Conventional sequence-based tests of neutral-
ity rely on alignment of homologous allelic sequences and on a
general model of neutral evolution such as the infinite alleles
model (22), neither of which can be applied to complex poly-
morphic repeat sequences. However, the analysis here on K1-
like alleles of MSP1 block 2 showed a lower variance in the
total repeat sequence length, compared to its constituent parts,
suggesting a selective constraint on the overall length. The
negative correlations between the lengths of the different re-
peat subregions indicates that such selection may operate on
each of them.
Consistent with this, human antibodies specific to the differ-
ent regions of the repeats were identified by using a panel of
K1-like synthetic peptides. The results showed that some per-
mutations of gain or loss of repeat motifs should influence the
antigenicity. Other studies have also shown that antibodies
react with diverse sequences in the K1-like repeats (10, 18).
Our aim was first to identify epitopes recognized by human
antibodies and murine MAbs to the K1-like repeat sequences
and then to design a minimal composite antigen sequence that
would contain these epitopes. MAbs recognized single de-
duced epitopes, with specificity consistent with expectations
from previous studies with native and recombinant antigens (5,
24). Sera from Nigerian and Gambian adults each recognized
between one and three deduced epitopes (a few had weaker
additional reactivities that were not resolved). All of these
epitopes were mapped schematically onto a sequence of 78
amino acids (containing 26 tripeptides), which was only slightly
longer than the longest naturally occurring individual K1-like
block 2 repeat that has been described (11).
This K1-like Super Repeat antigen was expressed as a GST
fusion protein for the purposes of direct comparison with two
FIG. 5. (A) Deduced specificity of antibodies from each of five mice immunized with the MSP1 block 2 K1-like Super Repeat antigen (K1SR),
and two groups of three mice immunized with the single allele repeat antigens (3D7 and Palo Alto), as determined by reactivity with synthetic
peptides (the same panel of 23 peptides described in Fig. 2 and 3) as displayed by horizontal lines at specific positions underneath a scheme of
the K1SR sequence. In cases where a deduced specificity maps to more than one place in the Super Repeat sequence, it is visually shown only once
(at the most N-terminal occurrence). (B) Deduced amino acid sequences of the MSP1 block 2 repeats in five P. falciparum cultured lines that have
K1-like block 2 alleles and titers of antibodies in sera from each of the five K1SR-immunized mice (and pooled sera) against schizonts of each of
the five cultured lines by immunofluorescence. Control sera raised to the GST carrier protein alone were negative, as were murine preimmune sera
(data not shown).
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individual K1-like allelic repeat antigens that were previously
made. The yield, solubility, and purification of the proteins
were similar, but the K1-like Super Repeat antigen had in-
creased polyvalent antigenicity compared to the others. The
K1-like Super Repeat contained multiple epitopes detected
with monoclonal and human antibodies. It reacted with anti-
bodies in more of the endemic human sera than either of the
individual K1-like allelic repeat antigens tested. When tested
by immunization of mice, the K1-like Super Repeat induced
antibodies that reacted with parasite lines possessing divergent
allelic sequences of the K1-like block 2, in contrast to mainly
subtype specific antibodies produced by mice immunized with
either of the individual K1-like allelic repeat antigens (32).
The present study demonstrates that complex allelic poly-
morphism based on repetitive sequences can be analyzed to
design a minimal composite antigen incorporating diverse de-
duced epitopes capable of eliciting a broad specificity response
after immunization. In order to develop the K1-like Super
Repeat as a vaccine candidate, it is being incorporated into
polyvalent hybrid protein constructs together with sequences
from two other major allelic types of MSP1 block 2 (MAD
20-like and R033-like), as well as potent T-cell epitopes to
elicit high-titer antibody responses and effective immunologi-
cal memory. In addition, the approach to polyvalent antigen
design described here could be extended to other malaria an-
tigens with complex polymorphic repeats, if these are also
identified to be likely targets of protective immune responses.
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